Immunoassays are inherently vulnerable to interference from heterophilic antibodies such as human anti-mouse antibodies (HAMA). Traditionally blockers are used to reduce heterophilic interference. The use of chimeric antibodies can also be used to solve HAMA interference by replacing constant domains of the mouse antibody with human antibody sequences. The resulting mouse/human chimeric antibody is not influenced by HAMA present in some clinical samples.
Meridian has just released new chimeric antibodies to cTnI which reduce the need for the use of expensive HAMA blockers in sensitive cTnI assays.